Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)
China · Delayed Price · Currency is CNY 19.90
+0.03 (0.15%)
May 29, 2026, 3:00 PM CST
SHA:600645 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1,389 | 1,423 | 1,550 | 1,538 | 1,507 | 1,497 |
Other Revenue | 32.11 | 32.11 | 35.81 | 52.07 | 47.8 | 37.94 |
| 1,421 | 1,455 | 1,585 | 1,590 | 1,555 | 1,535 | |
Revenue Growth (YoY) | -7.59% | -8.23% | -0.27% | 2.24% | 1.27% | 16.41% |
Cost of Revenue | 444.16 | 458.73 | 497.75 | 505.02 | 510.29 | 473.84 |
Gross Profit | 977.34 | 996.22 | 1,088 | 1,085 | 1,045 | 1,061 |
Selling, General & Admin | 638.12 | 650.04 | 695.33 | 719.77 | 723.4 | 749.78 |
Research & Development | 146.05 | 149.01 | 182.11 | 184.49 | 146.12 | 133.85 |
Other Operating Expenses | 22.63 | 22.34 | 19.39 | 19.19 | 17.59 | 16.54 |
Operating Expenses | 826.53 | 843.04 | 924.48 | 946.57 | 901.67 | 937.05 |
Operating Income | 150.82 | 153.18 | 163.2 | 138.14 | 142.93 | 124.44 |
Interest Expense | -3.23 | -3.23 | -5.03 | -5.02 | -4.02 | -3.14 |
Interest & Investment Income | 13.04 | 17.9 | 24.4 | 29.59 | 18.23 | 16.21 |
Earnings From Equity Investments | -13.67 | -13.67 | -14.3 | -11.85 | -7.96 | - |
Currency Exchange Gain (Loss) | 4.59 | 4.59 | -3.2 | 1.51 | -2.37 | 0.1 |
Other Non Operating Income (Expenses) | 3.16 | 0.1 | -3.22 | 1.03 | -2 | -1.49 |
EBT Excluding Unusual Items | 154.69 | 158.87 | 161.84 | 153.4 | 144.82 | 136.13 |
Impairment of Goodwill | - | - | - | - | - | -19.72 |
Gain (Loss) on Sale of Investments | 8.97 | 5.76 | -30.03 | -36.09 | -0.75 | 79.09 |
Gain (Loss) on Sale of Assets | 6.47 | 6.41 | 1.3 | 3.67 | 2.03 | 0.51 |
Asset Writedown | -2.37 | -1.35 | -4.68 | -0.31 | -0.8 | -6.26 |
Other Unusual Items | 7.69 | 4.76 | 7.52 | 11.92 | 9.9 | 33.2 |
Pretax Income | 175.45 | 174.45 | 135.95 | 132.59 | 155.21 | 222.96 |
Income Tax Expense | 73.32 | 70.92 | 46.59 | 34.03 | 48.53 | 71.75 |
Earnings From Continuing Operations | 102.13 | 103.53 | 89.35 | 98.55 | 106.68 | 151.21 |
Minority Interest in Earnings | 7.91 | 10.3 | 11 | 7.9 | 6.3 | 4.11 |
Net Income | 110.05 | 113.83 | 100.35 | 106.45 | 112.99 | 155.32 |
Net Income to Common | 110.05 | 113.83 | 100.35 | 106.45 | 112.99 | 155.32 |
Net Income Growth | 24.72% | 13.43% | -5.73% | -5.78% | -27.26% | - |
Shares Outstanding (Basic) | 460 | 455 | 456 | 463 | 471 | 471 |
Shares Outstanding (Diluted) | 460 | 455 | 456 | 463 | 471 | 471 |
Shares Change (YoY) | -0.36% | -0.18% | -1.45% | -1.69% | 0.02% | 0.17% |
EPS (Basic) | 0.24 | 0.25 | 0.22 | 0.23 | 0.24 | 0.33 |
EPS (Diluted) | 0.24 | 0.25 | 0.22 | 0.23 | 0.24 | 0.33 |
EPS Growth | 25.17% | 13.64% | -4.35% | -4.17% | -27.27% | - |
Free Cash Flow | 248.55 | 264.07 | 217.87 | 210.4 | 162.7 | 193.22 |
Free Cash Flow Per Share | 0.54 | 0.58 | 0.48 | 0.46 | 0.35 | 0.41 |
Gross Margin | 68.75% | 68.47% | 68.61% | 68.23% | 67.18% | 69.14% |
Operating Margin | 10.61% | 10.53% | 10.29% | 8.69% | 9.19% | 8.11% |
Profit Margin | 7.74% | 7.82% | 6.33% | 6.70% | 7.27% | 10.12% |
Free Cash Flow Margin | 17.48% | 18.15% | 13.74% | 13.23% | 10.46% | 12.58% |
EBITDA | 236.69 | 250.27 | 305.17 | 281.74 | 253.74 | 227.35 |
EBITDA Margin | 16.65% | 17.20% | 19.25% | 17.72% | 16.32% | 14.81% |
D&A For EBITDA | 85.87 | 97.09 | 141.97 | 143.6 | 110.81 | 102.91 |
EBIT | 150.82 | 153.18 | 163.2 | 138.14 | 142.93 | 124.44 |
EBIT Margin | 10.61% | 10.53% | 10.29% | 8.69% | 9.19% | 8.11% |
Effective Tax Rate | 41.79% | 40.65% | 34.27% | 25.67% | 31.26% | 32.18% |
Revenue as Reported | 1,421 | 1,455 | 1,585 | 1,590 | 1,555 | 1,535 |
Advertising Expenses | - | 26.53 | 30.86 | 32.98 | 29.02 | 32.43 |